PRTCY

14.9286.17%
JL

John L. LaMattina

Senior Independent Director

Dr. John L. LaMattina, Ph.D., had been an Independent Director of Immunome, Inc. since October 2017 until 2023. Dr. LaMattina has been a Senior Advisor since August 2017 and PCA Regenerative Medicine Advisory Board at Frequency Therapeutics, Inc. since March 2017. He serves as an Advisor of HemoShear Therapeutics, LLC. Dr. LaMattina has been Senior Partner of PureTech Health plc since 2009. Dr. LaMattina served as a Senior Advisor of Topokine Therapeutics, Inc. He served as the Chief Medical Officer of Pfizer Inc. Dr. LaMattina served as Senior Vice President of Pfizer Inc. since October 2003 and President of Global Research & Development from October 2003 to October 4, 2007. He spent at Pfizer Inc. Dr. LaMattina joined Pfizer as a medicinal chemist in 1977. During his career at Pfizer, he served various positions of increasing responsibility in research and development and served as its Senior Vice President of Worldwide Development since 1999. He served as Non-Employee Director of Larimar Therapeutics, Inc. Dr. LaMattina served as Vice President of Pfizer Inc. and served as its Executive Vice President of Pfizer Global Research & Development and President of Pfizer Worldwide Research & Technology Alliances since April 2000. He served as the Senior Vice President of Worldwide Discovery Operations for Pfizer Central Research from September 1998 to April 2000. Dr. LaMattina led the Pfizer's drug discovery and development efforts in the United States, Europe and Asia. Previously, he served as Vice President of Pfizer's U.S. Discovery unit since 1993. At Pfizer, his research involved seeking new therapeutic agents for the treatment of gastrointestinal disorders and also asthma. During his leadership tenure Pfizer discovered and/or developed several important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines. Dr. LaMattina had been the Chairman of Gelesis, Inc. from March 2010 to July 2019. He served on the board of directors of Gelesis Inc. from October 2009 to February 2019. He served as Chairman and Member of Global Advisory Board of Bilcare Limited. Dr. LaMattina serves as a Director of Ziarco Pharmaceuticals. He served as an Independent Director of Neurogen Corporation from February 2008 to 2010. Dr. LaMattina had been a Director of Vedanta Biosciences, Inc. since February 2012 until February 2026. He has been a Member of the Scientific Advisory Board at Trevena, Inc. since January 2009. Dr. LaMattina serves as a Member of the Scientific Advisory Board at Trevena pharmaceuticals. He has been an Independent Non-Executive Director of PureTech Health plc (formerly, PureTech Venture) since 2009 and Senior Independent Director since April 2025. Dr. LaMattina serves as a Director of Decision Options, LLC, Ziarco Pharmaceuticals. He serves as a Director of Worcester Polytechnic Institute. He served as a Member of Scientific Advisory Board at Topokine Therapeutics, Inc. He serves as a Member of the Board of Trustees for Boston College and for the Terri Brodeur Breast Cancer Foundation. Dr. LaMattina served as a Director at Human Genome Sciences Inc. from May 2008 to 2012. He served as a Director of Thermo Fisher Scientific, Inc. from January 2002 to November 9, 2006. He is the author of 23 scientific publications. He is the author of “Drug Truths: Dispelling the Myths About Pharma R&D”. He is also the Author of Devalued and Distrusted – Can the pharmaceutical industry restore its broken image and an author of the Drug Truths blog at Forbes.com. In 2010 he was the recipient of the American Chemical Society’s Earle B. Barnes Award for Leadership in Chemical Research Management. Dr. LaMattina received the 1998 Boston College Alumni Award of Excellence in Science and the 2004 American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes. Dr. LaMattina is a contributing writer to Forbes magazine. He was the recipient of the Just One Break, Inc. Lifetime Achievement Award and the Legal Momentum Equal Opportunity Award. Dr. LaMattina received an Honorary Doctor at Science degree from the University of New Hampshire in 2007, was a National Institutes of Health Postdoctoral Fellow in the Laboratory of Professor E. C. Taylor at Princeton University, a Ph.D. in Organic Chemistry from the University of New Hampshire in 1975 and graduated cum laude from Boston College in 1971 with a B.S. in Chemistry. He has been an Independent Director at Ligand Pharmaceuticals Incorporated since February 7, 2011. He was an Independent Director of Zafgen, Inc. from January 2014 until May 2020.

Positions